Intron Biotechnology signs MTA with European biotech firm for 'pHyal20' SC platform
Predicted impact: Low
Material transfer agreement for a platform; no financial terms disclosed.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.